PTEN-induced putative kinase 1-mediated autophagy pathway (PINK1-mediated autophagy pathway)

The **PINK1-mediated autophagy pathway**, often referred specifically as the **PINK1/Parkin-dependent mitophagy cascade**, is a critical cellular process responsible for identifying and removing damaged mitochondria through selective macroautophagic degradation ("mitophagy"). PTEN-induced putative kinase 1 (**PINK1**) is a serine/threonine protein kinase that accumulates on depolarized/damaged mitochondrial outer membranes where it phosphorylates both ubiquitin chains and Parkin E3 ligase. This leads Parkin from cytosol recruitment onto affected organelles, triggering polyubiquitination events that mark these organelles for engulfment by the core autolysosomal machinery. This process maintains healthy mitochondrial populations within cells—especially neurons—and defects contribute strongly toward pathogenesis seen in familial forms of Parkinson's disease and other neurodegenerative conditions. Modulating this axis pharmacologically remains an area under active investigation given its centrality in cellular homeostasis mechanisms related both directly and indirectly with aging-associated diseases.[2][4][6]

Other names

PINK1/Parkin pathwayPTEN-induced putative kinase 1-dependent mitophagyMitochondrial quality control via PINK1Mitophagy signaling cascade

Drugs that interact with this pathway generally aim to: - Enhance recruitment and activation of Parkin by stabilizing or activating PINK1 on damaged mitochondria - Promote phosphorylation events leading to ubiquitination and subsequent clearance of dysfunctional mitochondria via autolysosomal degradation[7] Semaglutide specifically was found experimentally to reduce oxidative stress and increase mitophagic flux through upregulation of ROS/PINK1/Parkin/p62 signaling components[7].